Clinical Trials › NCT06384976
Active, Not RecruitingPhase 2
KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis
Sponsored by Kyverna Therapeutics
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 120
Target enrollment
1
U.S. states
Sep 2024
Start date
Jan 2029
Expected completion
Interventions / Treatments
KYV-101Standard lymphodepletion regimenAnti-CD20 mAB
Conditions studied
Multiple Sclerosis, Primary ProgressiveMultiple Sclerosis, Secondary ProgressiveMultiple SclerosisMS
Where this trial is running (1 site)
California1 site
Palo Alto
Participating MS centers on MS Buddy (1)
Stanford MS & Neuroimmunology Clinic
Palo Alto, CA
Palo Alto, CA
MS centers in California
Compare treatment centers near a trial site by center type, providers and trials.
View California centersMore Phase 2 trials
Browse all Phase 2 MS trialsThe app
Check out the MS Buddy app
Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.